Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dechra Pharmaceuticals PLC Director's Dealing 2017

Sep 20, 2017

4797_dirs_2017-09-20_f77637f1-eac5-493a-b6d6-bd8df803ffcf.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3406R

Dechra Pharmaceuticals PLC

20 September 2017

20 September 2017

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

Notification and public disclosure of transactions by

persons discharging managerial responsibilities (PDMRs)

Sale of shares:

Dechra Pharmaceuticals PLC announces that on 19 September 2017, Ian Page and Tony Griffin sold the shares set out below. The shares were acquired pursuant to the Dechra Pharmaceuticals PLC Long Term Incentive Plan exercise announced on 19 September 2017. Ian Page sold shares to fund the tax liability arising on the exercise,  and Tony Griffin sold all the shares he acquired.

Name Capacity Shares Sold Sale Price

per share
Total beneficial shareholding following this announcement Percentage of issued share capital
Ian Page Director/PDMR 54,910 £20.23917 737,232 0.789%
Tony Griffin Director/PDMR 29,937 £20.23917 64,320 0.069%

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
2. Reason for the notification
a) Position/status Director/PDMR
b) Initial notification/

amendment
Initial Notification
3. Details of the Issuer
a) Name Dechra Pharmaceuticals PLC
b) LEI code N/A
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument

Identification code
Ordinary Shares of 1 pence each

ISIN: GB0009633180
b) Nature of the transaction Partial sale of shares obtained under the Company's Long Term Incentive Plan to satisfy tax liability
c) Price(s) and volumes(s) Price(s)

£20.23917
Volume(s)

54,910
d) Aggregated information

-   Aggregate volume

-   Price
54,910

£1,111,332.82
e) Date of the transaction 2017.09.19
f) Place of the transaction London Stock Exchange
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a) Name Tony Griffin
2. Reason for the notification
a) Position/status Director/PDMR
b) Initial notification/

amendment
Initial Notification
3. Details of the Issuer
a) Name Dechra Pharmaceuticals PLC
b) LEI code N/A
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument

Identification code
Ordinary Shares of 1 pence each

ISIN: GB009633180
b) Nature of the transaction Sale of shares obtained under the Company's Long Term Incentive Plan
c) Price(s) and volumes(s) Price(s)

£20.239137
Volume(s)

29,937
d) Aggregated information

-   Aggregate volume

-   Price
29,937

£605,899.04
e) Date of the transaction 2017.09.19
f) Place of the transaction London Stock Exchange

For further information, please contact:

Melanie Hall, Company Secretary                         

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHOKKDBPBKDNCB